CDK4/6i for HR+/HER2- MBC
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Released: August 19, 2021

Expiration: August 18, 2022

Matthew P. Goetz
Matthew P. Goetz, MD
Sara Hurvitz
Sara Hurvitz, MD

Activity

Progress
1
Course Completed